The theme for this year’s World AIDS Day is “Equalise and Integrate to End AIDS”. One aspect in which more equality is needed is between the quality of HIV testing services and aiming to test as many people as possible, argues René Sparks.
South Africa is expected to begin piloting the HIV prevention injection early next year as one of several projects that experts hope will reveal the answers to some of the biggest questions about the future of the shot – who will deliver the injection, where, and how to sell people on the idea that just six shots a year could protect them from HIV. Laura Lopez Gonzalez reports.
South Africa is expected to begin piloting the every-other-month HIV prevention shot early next year, according to the international medicine financing initiative Unitaid. New modelling shows that the injection could prevent as many as 52 000 new HIV infections in the next two decades. But to be cost-effective in South Africa, the research argues, the price of the injection must fall to levels drugmaker ViiV Healthcare says are unrealistic. Laura Lopez Gonzalez reports.
Elri Voigt summarises some of the latest developments on long-acting therapies for HIV presented at the 2022 International AIDS conference.
It is estimated that in 2021, around 0.3% of sexually active people in the Western Cape were taking antiretroviral medicines to prevent HIV infection. This is substantially lower than the national estimate of 1%. Elsabé Brits asks why uptake in the Western Cape is lagging behind most other provinces.
One of the hot topics at the recently concluded AIDS 2022 conference held in Montreal, Canada, was how HIV prevention interventions such as pills or injections that prevent HIV infection should be made available to different groups of people. Tiyese Jeranji spoke to some local experts and an activist about the rich set of discussions.
The world stands at an inflection point once more in the war against HIV. For those of us working in the field in South Africa, especially, it feels eerily like the battle that was fought 25 years ago, writes Dr Liesl Page-Shipp.
In 2021, HIV was successfully suppressed in the bodies of around 63% of the close to eight million people living with HIV in South Africa. This is according to recent outputs from Thembisa, the leading mathematical model of HIV in South Africa. With the help of some graphs, Spotlight editor Marcus Low unpacks this and other key model outputs.
The National Department of Health says that lubricant should be freely available alongside condoms at clinics around the country. But according to community-led monitoring group Ritshidze, clinics often do not offer lubricant. Biénne Huisman reports on why access to lubricant is important for HIV prevention and why oil-based lubricants should not be used with condoms.
The South African Health Products Regulatory Authority recently approved the use of the monthly dapivirine vaginal ring for women 18 years and older to reduce the risk of HIV infection. Thabo Molelekwa looks at the evidence for the ring’s efficacy and asks what plans there are for making it available to women in South Africa.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
Even though the rate of new HIV infections in young women and adolescent girls remains stubbornly high, provision and uptake of pills that can prevent HIV infection have generally been slow and lagging. One potential solution presented at the recent Conference on Retroviruses and Opportunistic Infections is to provide the pills at schools. Tiyese Jeranji reports.
